Research graph
References from Engineering lipid-based nanocarriers for PROTAC delivery: evaluating the influence of manufacturing and morphology on pharmacokinetic exposure. Local targets link to admitted publications; unresolved targets remain external evidence.
Estrogen receptor-α targeting: PROTACs, SNIPERs, peptide-PROTACs, antibody conjugated PROTACs and SNIPERs
10.3390/pharmaceutics14112523 · 2022 · External reference
Selectively targeting estrogen receptors for cancer treatment
10.1016/j.addr.2010.08.001 · 2010 · External reference
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
10.7554/elife.15828 · 2016 · External reference
Proteolysis targeting chimeras (PROTACs) — past, present and future
10.1016/j.ddtec.2019.01.002 · 2019 · External reference
Integrating proteolysis‐targeting chimeras (PROTACs) with delivery systems for more efficient and precise targeted protein degradation
10.1002/marc.202401051 · 2025 · External reference
Lessons in PROTAC design from selective degradation with a promiscuous warhead
10.1016/j.chembiol.2017.09.010 · 2018 · External reference
PROTAC targeted protein degraders: the past is prologue
10.1038/s41573-021-00371-6 · 2022 · External reference
Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs
10.1016/j.ebiom.2018.09.005 · 2018 · External reference
BCS class IV drugs: highly notorious candidates for formulation development
10.1016/j.jconrel.2017.01.014 · 2017 · External reference
Delivering on the promise of protein degraders
10.1038/s41573-023-00652-2 · 2023 · External reference
A review on liposome-based therapeutic approaches against malignant melanoma
10.1016/j.ijpharm.2021.120413 · 2021 · External reference
Simultaneous encapsulation of hydrophilic and lipophilic molecules in liposomes of DSPC
10.1016/j.tca.2019.178462 · 2020 · External reference
Lipid nanoparticle technology for clinical translation of siRNA therapeutics
10.1021/acs.accounts.9b00368 · 2019 · External reference
A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives
10.3390/molecules27041372 · 2022 · External reference
Challenges and opportunities in the development of complex generic long-acting injectable drug products
10.1016/j.jconrel.2021.06.017 · 2021 · External reference
Flash nanoprecipitation assisted self-assembly of ionizable lipid nanoparticles for nucleic acid delivery
10.1039/d4nr00278d · 2024 · External reference
Using microfluidics for scalable manufacturing of nanomedicines from bench to GMP: a case study using protein-loaded liposomes
10.1016/j.ijpharm.2020.119266 · 2020 · External reference
Use of microfluidics to prepare lipid-based nanocarriers
10.3390/pharmaceutics15041053 · 2023 · External reference
Development of liposome systems for enhancing the PK properties of bivalent PROTACs
10.3390/pharmaceutics15082098 · 2023 · External reference
Optimization of lipodisk properties by modification of the extent and density of the PEG corona
10.1016/j.jcis.2016.08.067 · 2016 · External reference
A systematic approach for liposome and lipodisk preclinical formulation development by microfluidic technology
10.1208/s12248-021-00651-4 · 2021 · External reference
Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation
10.1016/j.ejpb.2005.05.009 · 2006 · External reference
RGD-modified lipid disks as drug carriers for tumor targeted drug delivery
10.1039/c5nr05577f · 2016 · External reference
Rapid and scale-independent microfluidic manufacture of liposomes entrapping protein incorporating in-line purification and at-line size monitoring
10.1016/j.ijpharm.2018.11.060 · 2019 · External reference
Microfluidics based manufacture of liposomes simultaneously entrapping hydrophilic and lipophilic drugs
10.1016/j.ijpharm.2016.09.027 · 2016 · External reference
Liposomes, methods and protocols
10.1007/978-1-4939-6591-5_2 · 2016 · External reference
Development and in vitro evaluation of lipodisks optimized for co-delivery of chemotherapeutic drugs and membranolytic anticancer peptides
10.1016/j.jcis.2025.138173 · 2025 · External reference
Unresolved reference
External reference
A fast and high-quality charge model for the next generation general AMBER force field
10.1063/5.0019056 · 2020 · External reference
Efficient generation of high‐quality atomic charges. AM1‐BCC model: II. Parameterization and validation
10.1002/jcc.10128 · 2002 · External reference
10.1021/acs.jcim.3c01153
10.1021/acs.jcim.3c01153 · 2023 · External reference
The amber biomolecular simulation programs
10.1002/jcc.20290 · 2005 · External reference
Multidimensional free‐energy calculations using the weighted histogram analysis method
10.1002/jcc.540161104 · 1995 · External reference
Assessing liposomal nanocarriers for targeted drug delivery through electroporation
10.1016/j.ijpharm.2025.125708 · 2025 · External reference
Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application
10.3390/pharmaceutics14030543 · 2022 · External reference
Process robustness in lipid nanoparticle production: a comparison of microfluidic and turbulent jet mixing
10.1021/acs.molpharmaceut.3c00390 · 2023 · External reference
Kinetically controlled and nonequilibrium assembly of block copolymers in solution
10.1021/jacs.4c03314 · 2024 · External reference
Precise control of liposome size using characteristic time depends on solvent type and membrane properties
10.1038/s41598-023-31895-z · 2023 · External reference
Barotropic phase transitions of dioleoylphosphatidylcholine and stearoyl-oleoylphosphatidylcholine bilayer membranes
10.1016/s0005-2736(98)00122-9 · 1998 · External reference
